The ribonucleotide reductase inhibitor (E)-2′-fluoromethylene-2′-deoxycytidine (MDL 101,731): a potential topical therapy for herpes simplex virus infection

Antiviral Research

Volumn 27, Issue 4, 1995, Pages 325-334

  Bridges, C Gordon ^a   Ahmed, S Parvin ^a   Sunkara, Prasad S ^b   McCarthy, James R ^b   Tyms, A Stanley ^a  

^a MEDICAL RESEARCH COUNCIL   (United Kingdom)

^b Merrell Dow Research Institute   (United States)

Author keywords

HSV; MDL 101,731; Ribonucleotide reductase; Zosteriform rash model

Indexed keywords

ACICLOVIR; ANTIVIRUS AGENT; ENZYME INHIBITOR; RIBONUCLEOTIDE REDUCTASE; TEZACITABINE; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIVIRAL ACTIVITY; ARTICLE; CONTROLLED STUDY; DRUG ACTIVITY; EXPERIMENTAL INFECTION; FEMALE; HERPES SIMPLEX; MOUSE; NONHUMAN; PRIORITY JOURNAL; TOPICAL DRUG ADMINISTRATION; VIRUS REPLICATION;

ACYCLOVIR; ADMINISTRATION, TOPICAL; ANIMAL; ANTIVIRAL AGENTS; DEOXYCYTIDINE; DISEASE MODELS, ANIMAL; ENZYME INHIBITORS; FEMALE; HERPES SIMPLEX; HERPESVIRUS 1, HUMAN; HERPESVIRUS 2, HUMAN; MICE; MICE, INBRED BALB C; MOLECULAR STRUCTURE; RIBONUCLEOTIDE REDUCTASES;

ANIMALIA; HERPES; HUMAN HERPESVIRUS 1; MURINAE; SIMPLEXVIRUS;

EID: 0029125092     PISSN: 01663542     EISSN: None     Source Type: Journal    
DOI: 10.1016/0166-3542(95)00015-E     Document Type: Review

References (24)

1. Solar stimulator-induced herpes labialis: use in evaluating treatment with acyclovir plus 348U87
2. The herpes simplex virus ribonucleotide reductase is required for ocular virulence
3. Ribonucleotide reductase encoded by herpes simplex virus is a determinant of the pathogenicity of the virus in mice and a valid antiviral target
4. Treatment of primary first episode genital herpes simplex virus infections with acyclovir: results of topical, intravenous and oral therapy
5. Role of viral ribonucleotide reductase in the increase of dTTP pool size in herpes simplex virus-infected Vero cells
6. Successful treatment of herpes labialis with topical acyclovir
7. Herpes simplex virus type-1 induced ribonucleotide reductase activity is dispensible for virus growth and DNA synthesis: isolation and characterization of a ICP6 lacZ insertion mutant
8. Deletion of herpes simplex virus type 1 ribonucleotide reductase gene alters virulence and latency in vivo
9. A herpes simplex virus ribonucleotide reductase deletion mutant is defective for productive acute and reactivatable latent infections of mice and for replication in mouse cells
10. Synergystic topical therapy by acyclovir and A1110U for herpes simplex virus induced zosteriform rash
11. A collaborative study of patient-initiated treatment of recurrent genital herpes with topical acyclovir or placebo
12. Design, synthesis and antitumour activity of an inhibitor of ribonucleotide reductase
13. Stereospecific method to E and Z terminal fluoro olefins and its application to the synthesis of 2′-deoxy-2′-fluoromethylene nucleosides as potential inhibitors of ribonucleoside diphosphate reductase
14. Efficacy of oral acyclovir in the treatment of initial and recurrent genital herpes
15. Oral acyclovir and herpes labialis: a randomised, double-blind, placebo-controlled study
16. Acyclovir: mechanism of antiviral action and potentiation by ribonucleotide reductase inhibitors
17. Failure of acyclovir cream in treatment of recurrent herpes labialis
18. Zosteriform spread of herpes simplex virus as a model of recrudescence and its use to investigate the role of immune cells in prevention of recurrent disease
19. Potentiation of antiherpetic activity of acyclovir by ribonucleotide reductase inhibition
20. 2-Acetylpyridine 5-[(dimethylamino)thiocarbonyl]-thiocarbonohydrazone (A1110U), a potent inactivator of ribonucleotide reductases of herpes simplex and varicella-zoster viruses and a potentiator of acyclovir
21. Inactivators of herpes simplex virus ribonucleotide reductase: haematological profiles and in vivo potentiation of the antiviral activity of acyclovir
22. Antitumor activity of (E)-2′-fluoromethylene-2′-deoxycytidine (FMdC, MDL 101,731): a novel inhibitor of ribonucleotide reductase
23. The in vitro activity of acyclovir and related compounds against cytomegalovirus infections
24. Acyclovir: a decade later